Research indicates that kidney disease risk scores are most effective when based on African genomic data, challenging the “one-size-fits-all” approach in global medicine.
Summary
A major pan-African genomic study shows that kidney disease—already one of the fastest-growing causes of death in Africa—is influenced by a complex interaction of genetic and environmental factors.
By analysing data from more than 100,000 people of African ancestry, researchers identified several new genetic variants linked to kidney function. The findings also highlight that risk prediction models are more accurate when they are developed using African-specific genomic data, reinforcing the importance of locally relevant medical research.
Kidney disease often develops silently, gradually reducing kidney function over time. The kidneys normally filter about 200 litres of blood daily, removing waste and balancing fluids and salts. When they fail, patients may face severe complications such as fatigue, fluid retention, cardiovascular problems, and in advanced cases, require dialysis or a transplant.
Globally, kidney disease is a major and growing health burden, affecting around 850 million people and causing approximately 1.5 million deaths annually. The condition is often undetected until it reaches an advanced stage.
The burden is especially severe among people of African ancestry, who are significantly more likely to develop end-stage kidney failure. In sub-Saharan Africa, rising rates of hypertension and type 2 diabetes—both major risk factors—are worsening the situation, while limited access to specialists and treatment further increases the impact. In many countries, kidney care services are extremely scarce.
The study, conducted by the KidneyGenAfrica consortium, analysed genetic data from populations across eastern, western, and southern Africa, as well as individuals of African ancestry living abroad. Researchers used genome-wide association analysis to identify genetic regions linked to kidney function.
The results revealed multiple previously unknown genetic variants and showed that risk prediction tools perform better when based on genetically similar African populations. The study also found that a gene known as APOL1, previously linked to kidney disease risk in African Americans, behaves differently in continental African populations.
Researchers stress that early detection, improved healthcare investment, and inclusion of African populations in clinical trials are essential for improving outcomes. They also call for greater investment in African genomic research infrastructure to strengthen future prevention and treatment strategies.
About the Author
